OmniAb, Inc. OABI

Nasdaq · Approved · EDGAR · Updated Oct 30, 2026

OmniAb, Inc. (Nasdaq: OABI) is a drug developer. Its lead program is marketed.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Oct 30, 2026
n/a OmniAb entered into a new global collaboration and license agreement with Eli Lilly for a new ion channel program with an up-front payment and up to $370 million in milestones plus royalties.During the third quarter of 2026, OmniAb entered into a new global collaboration and license agreement with Eli Lilly and Company for a new ion channel program. Filing
Oct 30, 2026
met Teva announced positive topline results from Phase 2a study of TEV-'408 in celiac disease, meeting the primary endpoint of statistically significant prevention of gluten-induced intestinal damage versus placebo.Teva Pharmaceuticals announced positive topline results from an ongoing Phase 2a study of TEV-'408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevent Filing
Oct 22, 2026
approval China's NMPA approved batoclimab for treatment of generalized myasthenia gravis in adult patients who are anti-AChR antibody positive.On October 22, Harbour BioMed announced that the National Medical Products Administration (NMPA) of China has approved the Biologics License Application for batoclimab injection, for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) ant Filing

1 more on record.

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export